Cargando…
Impact of orphan drugs on Latvian budget
BACKGROUND: Number of orphan medicinal products on the market and number of rare disease patients, taking these usually expensive products, are increasing. As a result, budget impact of orphan drugs is growing. This factor, along with the cost-effectiveness of orphan drugs, is often considered in th...
Autores principales: | Logviss, Konstantins, Krievins, Dainis, Purvina, Santa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864910/ https://www.ncbi.nlm.nih.gov/pubmed/27169704 http://dx.doi.org/10.1186/s13023-016-0434-y |
Ejemplares similares
-
Rare diseases and orphan drugs: Latvian story
por: Logviss, Konstantins, et al.
Publicado: (2014) -
Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study
por: Logviss, Konstantins, et al.
Publicado: (2018) -
Estimating the budget impact of orphan drugs in Sweden and France 2013–2020
por: Hutchings, Adam, et al.
Publicado: (2014) -
Variability of Seed Germination and Dormancy Characteristics and Genetic Analysis of Latvian Avena fatua Populations
por: Ņečajeva, Jevgenija, et al.
Publicado: (2021) -
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
por: Schey, Carina, et al.
Publicado: (2011)